{"id":"inhaled-epoprostenol-and-phenylephrine","safety":{"commonSideEffects":[{"rate":null,"effect":"Systemic hypotension"},{"rate":null,"effect":"Jaw pain"},{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tremor (from phenylephrine)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoprostenol is a prostacyclin analog that binds to prostacyclin receptors on pulmonary vascular smooth muscle, causing selective pulmonary vasodilation and reducing right ventricular afterload. Phenylephrine is an alpha-1 adrenergic agonist added to counteract systemic hypotension that may result from epoprostenol's vasodilatory effects, thereby maintaining systemic perfusion pressure while allowing targeted pulmonary benefit.","oneSentence":"Inhaled epoprostenol acts as a pulmonary vasodilator via prostacyclin receptor activation, while phenylephrine provides systemic vasoconstriction to maintain blood pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:56.881Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary hypertension (inhaled formulation for acute vasodilator testing or chronic therapy)"}]},"trialDetails":[{"nctId":"NCT02748265","phase":"PHASE4","title":"Nebulized Epoprostenol (FLOLAN) and Phenylephrine on One Lung Ventilation (OLV)","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-03","conditions":"Oxygenation During One Lung Ventilation","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prostacyclin"],"phase":"marketed","status":"active","brandName":"Inhaled Epoprostenol and phenylephrine","genericName":"Inhaled Epoprostenol and phenylephrine","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhaled epoprostenol acts as a pulmonary vasodilator via prostacyclin receptor activation, while phenylephrine provides systemic vasoconstriction to maintain blood pressure. Used for Pulmonary hypertension (inhaled formulation for acute vasodilator testing or chronic therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}